Cara Therapeutics, Inc.

NASDAQ: CARA
$0.89
-$0.06 (-5.9%)
Closing price February 28, 2024
Thursday's top analyst upgrades and downgrades included AGNC Investment, Costco Wholesale, CrowdStrike, Dick’s Sporting Goods, Fifth Third Bancorp, General Electric, PayPal, Sabre, Six Flags...
Tuesday afternoon's top analyst upgrades and downgrades included Biogen, BP, Caterpillar, Riot Blockchain, Squarespace and more.
Cara Therapeutics shares were crushed on Tuesday after the firm announced results from its midstage trial in patients with chronic kidney disease.